451 related articles for article (PubMed ID: 33144318)
1. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
Shang R; Song X; Wang P; Zhou Y; Lu X; Wang J; Xu M; Chen X; Utpatel K; Che L; Liang B; Cigliano A; Evert M; Calvisi DF; Chen X
Gut; 2021 Sep; 70(9):1746-1757. PubMed ID: 33144318
[TBL] [Abstract][Full Text] [Related]
2. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib: An evolving therapy for hepatocellular carcinoma.
El-Khoueiry AB; Hanna DL; Llovet J; Kelley RK
Cancer Treat Rev; 2021 Jul; 98():102221. PubMed ID: 34029957
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Wang H; Zhou Y; Xu H; Wang X; Zhang Y; Shang R; O'Farrell M; Roessler S; Sticht C; Stahl A; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2022 Oct; 76(4):951-966. PubMed ID: 35076948
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
Kelley RK; W Oliver J; Hazra S; Benzaghou F; Yau T; Cheng AL; Rimassa L
Future Oncol; 2020 Jul; 16(21):1525-1536. PubMed ID: 32491932
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives.
Trojan J
Drugs; 2020 Aug; 80(12):1203-1210. PubMed ID: 32671719
[TBL] [Abstract][Full Text] [Related]
9. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib for the treatment of hepatocellular carcinoma.
Personeni N; Rimassa L; Pressiani T; Smiroldo V; Santoro A
Expert Rev Anticancer Ther; 2019 Oct; 19(10):847-855. PubMed ID: 31603008
[No Abstract] [Full Text] [Related]
11. Cabozantinib as a second-line treatment option in hepatocellular carcinoma.
D'Angelo A; Sobhani N; Bagby S; Casadei-Gardini A; Roviello G
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):623-629. PubMed ID: 32394749
[TBL] [Abstract][Full Text] [Related]
12. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression.
Yang X; Shi J; Chen X; Jiang Y; Zhao H
Oncologist; 2020 Jun; 25(6):470-474. PubMed ID: 32100934
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein.
Xiang QF; Zhang DM; Wang JN; Zhang HW; Zheng ZY; Yu DC; Li YJ; Xu J; Chen YJ; Shang CZ
Liver Int; 2015 Mar; 35(3):1010-23. PubMed ID: 24621440
[TBL] [Abstract][Full Text] [Related]
16. Molecular therapies for HCC: Looking outside the box.
Faivre S; Rimassa L; Finn RS
J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Kelley RK; Verslype C; Cohn AL; Yang TS; Su WC; Burris H; Braiteh F; Vogelzang N; Spira A; Foster P; Lee Y; Van Cutsem E
Ann Oncol; 2017 Mar; 28(3):528-534. PubMed ID: 28426123
[TBL] [Abstract][Full Text] [Related]
18. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
19. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
20. CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation.
Wang DD; Chen Y; Chen ZB; Yan FJ; Dai XY; Ying MD; Cao J; Ma J; Luo PH; Han YX; Peng Y; Sun YH; Zhang H; He QJ; Yang B; Zhu H
Mol Cancer Ther; 2016 Dec; 15(12):2916-2925. PubMed ID: 27638856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
